How it works

Zilucoplan is a new medicine developed to treat those with acetylcholine receptor-positive (AChR) myasthenia gravis (MG). Zilucoplan is a complement inhibitor, meaning it works to prevent activation of the complement pathway, a key element of the immune response. Complement inhibitors can be helpful in relieving the damage that can occur at the site of communication between nerve and muscle cells that occurs in MG.

How it is delivered

Zilucoplan can be administered subcutaneously via injection. This can be done at home.

When you have it

It is administered once daily. It is currently the only once-daily gMG targeted therapeutic that can be self-administered in AChR antibody-positive MG.

Side effects

All new medicines can cause unwanted side effects. When starting zilucoplan, you may experience the following:

·        Injection site reaction

·        Diarrhoea

·        Upper respiratory tract infection

·        Headache

If these symptoms persist, speak to your doctor. Please consult with your doctor for an extended list of possible side effects.

Related UK companies

UCB (developer) 

Treatments